141 related articles for article (PubMed ID: 2866061)
1. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.
Gibson PR; Jewell DP
Clin Sci (Lond); 1985 Aug; 69(2):177-84. PubMed ID: 2866061
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.
Aparicio-Pagés MN; Verspaget HW; Hafkenscheid JC; Crama-Bohbouth GE; Peña AS; Weterman IT; Lamers HW
Gut; 1990 Sep; 31(9):1030-2. PubMed ID: 1976576
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
Rhodes JM; Bartholomew TC; Jewell DP
Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
[TBL] [Abstract][Full Text] [Related]
4. Increased suppressor cell activity in inflammatory bowel disease.
Holdstock G; Chastenay BF; Krawitt EL
Gut; 1981 Dec; 22(12):1025-30. PubMed ID: 6119275
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of prostaglandin synthetase in human rectal mucosa.
Hawkey CJ; Lo Casto M
Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
[TBL] [Abstract][Full Text] [Related]
6. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes.
Shanahan F; Niederlehner A; MacDermott RP; Stenson WF; Kane MG; Targan S
Immunopharmacology; 1986 Apr; 11(2):111-8. PubMed ID: 2872187
[TBL] [Abstract][Full Text] [Related]
8. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.
Allgayer H; Eisenburg J; Paumgartner G
Eur J Clin Pharmacol; 1984; 26(4):449-51. PubMed ID: 6428914
[TBL] [Abstract][Full Text] [Related]
9. Products of the lipoxygenase pathway in human natural killer cell cytotoxicity.
Rossi P; Lindgren JA; Kullman C; Jondal M
Cell Immunol; 1985 Jun; 93(1):1-8. PubMed ID: 2986854
[TBL] [Abstract][Full Text] [Related]
10. The nature of the natural killer (NK) cell of human intestinal mucosa and mesenteric lymph node.
Gibson PR; Jewell DP
Clin Exp Immunol; 1985 Jul; 61(1):160-8. PubMed ID: 2412737
[TBL] [Abstract][Full Text] [Related]
11. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
Bird HA
Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
[TBL] [Abstract][Full Text] [Related]
12. The effects of aminosalicylic acid derivatives on nitric oxide in a cell-free system.
Reynolds PD; Middleton SJ; Shorthouse M; Hunter JO
Aliment Pharmacol Ther; 1995 Oct; 9(5):491-5. PubMed ID: 8580268
[TBL] [Abstract][Full Text] [Related]
13. Reversible inhibition of lymphokine-activated killer cell activity by lipoxygenase-pathway inhibitors.
Sibbitt WL; Imir T; Bankhurst AD
Int J Cancer; 1986 Oct; 38(4):517-21. PubMed ID: 3019899
[TBL] [Abstract][Full Text] [Related]
14. Human natural killer cell activity is reversibly inhibited by antagonists of lipoxygenation.
Seaman WE
J Immunol; 1983 Dec; 131(6):2953-7. PubMed ID: 6417236
[TBL] [Abstract][Full Text] [Related]
15. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
Tornhamre S; Edenius C; Smedegård G; Sjöquist B; Lindgren JA
Eur J Pharmacol; 1989 Oct; 169(2-3):225-34. PubMed ID: 2572437
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by peripheral blood and intestinal mononuclear cells from control and inflammatory bowel disease patients.
MacDermott RP; Kane MG; Steele LL; Stenson WF
Immunopharmacology; 1986 Apr; 11(2):101-9. PubMed ID: 2872186
[TBL] [Abstract][Full Text] [Related]
17. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of antibody secretion by 5-aminosalicylic acid.
MacDermott RP; Schloemann SR; Bertovich MJ; Nash GS; Peters M; Stenson WF
Gastroenterology; 1989 Feb; 96(2 Pt 1):442-8. PubMed ID: 2562949
[TBL] [Abstract][Full Text] [Related]
19. Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.
Roediger W; Schapel G; Lawson M; Radcliffe B; Nance S
Biochem Pharmacol; 1986 Jan; 35(2):221-5. PubMed ID: 2867767
[TBL] [Abstract][Full Text] [Related]
20. The effects of sulphasalazine and its metabolites on prostaglandin production by human mononuclear cells.
Punchard NA; Boswell DJ; Greenfield SM; Thompson RP
Biochem Pharmacol; 1992 Jun; 43(11):2369-76. PubMed ID: 1351726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
